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The PROTECT-TAVI Trial (PROphylactic effecT of
furosEmide-induCed diuresis with matched isotonic
intravenous hydraTion in Transcatheter Aortic Valve
Implantation)*Charanjit S. Rihal, MD,y Kianoush B. Kashani, MDzI n this issue of JACC: Cardiovascular Interventions,Barbanti et al. (1) report the results of a single-center, prospective, randomized, controlled trial
(RCT) investigating the potential protective effect of
the RenalGuard system in patients undergoing trans-
catheter aortic valve replacement (TAVR). Acute kid-
ney injury (AKI) is an important ﬁnding after
interventional and operative procedures and is associ-
atedwith a signiﬁcantly adverse prognosis after percu-
taneous coronary intervention (PCI) or TAVR.
Numerous approaches to prevent post-procedural
AKI have been studied, including various contrast
agents, renal protective drugs, and hydration regi-
mens. Almost all have failed in large RCTs with theSEE PAGE 1595exception of simply limiting contrast dose and
ensuring adequate pre-procedural hydration. Patients
undergoing TAVR, in particular, are at high risk, not
only at risk of AKI but of subsequent cardiac and*Editorials published in JACC: Cardiovascular Interventions reﬂect the
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were quite typical of those undergoing TAVR in Europe
and North America, with a median age older than 80
years and high prevalences of hypertension (75%), dia-
betes mellitus, dyspnea, previous heart failure, and
peripheral vascular disease, all factors associated
with a higher risk of AKI. Although themean estimated
glomerular ﬁltration rate (GFR) was not unreasonable,
w10% of patients had severe baseline renal dysfunc-
tion (estimated GFR <30 ml/min), and almost 50%
had moderate renal dysfunction (estimated GFR 30 to
60 ml/min). The TAVR procedures themselves (major-
ity CoreValve) were well executed by this experienced
group with high device success rates and a low inci-
dence of permanent pacemaker implantation. Rapid
pacing, which induces hypotension, was used in all
cases, and the median contrast volume administered
was relatively high at 175 ml (interquartile range up
to 230 ml).
Logistically, the trial was a single-center, prospec-
tive RCT, and the authors are to be congratulated for
this design as opposed to simply performing a
consecutive case series. Due to the single-center na-
ture of the trial, a relatively small number of patients
were randomized, 56 per group, which, unfortu-
nately, is typical of many early studies in the ﬁeld of
AKI prevention.
The RenalGuard system (RenalGuard Solutions
Inc., Milford, Massachusetts) is a unique proprietary
technology and is approved for sale in Europe. The
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1606system causes renal ﬂushing by carefully matching
intravenous infusion of isotonic saline solution to
furosemide-forced diuresis. The current study de-
monstrated a lower incidence of AKI as assessed by
increases in serum creatinine (stage 1 AKI, 5.4% of
the treatment group vs. 23.2% of the control group;
p ¼ 0.013). Although at ﬁrst glance this appears
impressive, in almost all cases, the creatinine level
returned to normal, and no patient required hemo-
dialysis. Moreover, there was no signiﬁcant differ-
ence in other important clinical endpoints, either
cardiac or noncardiac, between groups. Stage 3 AKI
developed in only 1 patient in the control group. This
particular patient received 300 ml of contrast during
the procedure and experienced a creatinine peak of
almost 6 mg/dl despite a baseline estimated GFR of
63.8 ml/min. It is unclear whether this 84-year-old
patient was also diabetic.
These observations lead to a number of interesting
questions. First, although the RenalGuard system
does appear to lower post-procedural creatinine in-
creases, does it actually prevent renal dysfunction or
merely ﬂush serum creatinine? Second, is serum
creatinine an appropriate biomarker for AKI in this
model? It should be remembered that creatinine is a
break-down product of creatine phosphate in muscle
tissue, and w1% to 2% of muscle creatine is con-
verted to creatinine daily. Creatinine is eliminated
both by ﬁltration and tubular excretion, and, in a
steady state serum creatinine concentrations, reﬂects
underlying GFR. We previously suggested that
even hydration may actually be diluting serum
creatinine (2). With the RenalGuard system, the ef-
fects of renal ﬂushing on kidney physiology need to
be accounted for.
Glomerular ﬁltration rate changes constantly to
accommodate the variations in the osmolar load.
Osmolar load varies based on the diet and the rate of
protein breakdown. When a patient is faced with a
large osmolar load, the GFR drastically increases, and
elimination of the additional osmoles is enhanced. In
the kidney, the elimination process is tightly regu-
lated by tubuloglomerular feedback (TGF) (3). During
TGF, enhanced sodium chloride delivery to the loop
of Henle and distal convoluted tubules results in
signiﬁcant afferent arteriolar vasoconstriction. This
mechanism is orchestrated via a chloride-sensitive
signaling process through the juxtaglomerular appa-
ratus. As the result, nephrons avoid rapid loss of
electrolytes and maintain GFR in the physiological
range. Loop diuretics block this signaling process,
and afferent arteriolar vasoconstriction is avoided.
With RenalGuard, however, the GFR increases
signiﬁcantly due to a rapid load of osmoles receivedin the form of normal saline. Unlike physiological
scenarios, TGF is not able to modulate the enhanced
GFR due to the blocking effect of furosemide on the
juxtaglomerular apparatus. This results in a signiﬁ-
cant increase in GFR during RenalGuard use. This
hyperﬁltration will increase elimination of serum
creatinine. When an intervention, such as Renal-
Guard, directly affects the serum creatinine level,
the outcome of interest (renal function) cannot be
adequately assessed based on the serum creatinine
level alone.
In the current study, patients in the control group
are in a disadvantageous position because they likely
(data are not provided in the paper) received a much
smaller osmolar load because they did not need to
reach 300 ml/h of urine output. Therefore, the GFR
would not be expected to increase to the same
extent in the control group as in the intervention
group. Moreover, the control group did not receive
furosemide to mitigate TFG, and the chloride load in
this group could actually have enhanced afferent
arteriolar vasoconstriction. The sum total of these
effects in the control group, particularly coupled
with the vasoconstrictive characteristics of contrast
media, may have resulted in severe vasoconstriction
of the afferent arteriole and decreases in the GFR.
We suspect that it is this physiological phenomenon
that has been detected as stage 1 AKI in the
current study. Information regarding osmolar load
and elimination (amount of osmoles received and
osmolar excretion via urine) in each arm of the study
would have helped to delineate this issue. Finally,
the extent of tubular cell damage in each group is
unclear as there were no renal stress or injury bio-
markers measured.
What, then, can we conclude from the current
paper? First, the RenalGuard system appears to be
safe to use in patients undergoing TAVR and is
associated with lower creatinine increases, but there
are no differences in important clinical endpoints,
including need for hemodialysis. We are not
convinced that serum creatinine is an appropriate
sole marker for AKI when a renal ﬂushing system is
being used for the reasons outlined previously.
Finally, the RenalGuard system should be evaluated
in a larger multicenter trial enrolling patients at
moderate to high risk of post-procedural AKI,
whether that be TAVR or PCI. Such a trial should
incorporate more robust markers of kidney func-
tion, such as iothalamate clearance and cystatin C,
in conjunction with kidney stress and injury bio-
markers (e.g., insulin-like growth factor binding
protein-7 and tissue inhibitor metalloproteinase-2
[4], neutrophil gelatinase–associated lipocalin [5],
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1607kidney injury molecule-1 [6]). Until such trials are
performed, we believe that it is premature to
advocate widespread adoption of renal ﬂushing for
the prevention of AKI.REPRINT REQUESTS AND CORRESPONDENCE: Dr.
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